Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Watch E I Du Pont De Nemours And Co (DD) Make Hay Down on the Farm

What follows may seem rather oxymoronic, because E I Du Pont De Nemours And Co (NYSE:DD) missed per-share earnings expectations by a full $0.16 this week. Nevertheless, I’m convinced that, for several reasons, the company’s shares currently constitute a far better buy than a sell.

E I Du Pont De Nemours And CoAs a quick recap, the venerable Delaware-based company, whose history dates back to Jefferson’s presidency, checked in with net income of $1.03 billion, or $1.11 per share. Those results compared with $1.17 per share, or $1.23 per share, for the second quarter of 2012. Analysts who monitor the company had expected the per-share number for the most recent quarter to reach $1.27. E I Du Pont De Nemours And Co (NYSE:DD)’s revenue dipped by a single percentage point, to $9.8 billion.

Agriculture’s blooming

As might have been expected, agriculture,E I Du Pont De Nemours And Co (NYSE:DD)’s biggest unit at nearly 37% of total revenues, was the strongest segment, turning in a 7% hike in revenues. That made for an 11% sales gain for the first half of the year.

Conversely, the performance-chemicals segment was the caboose for the quarter, suffering a 15% revenue drop, and a 56% plummet in operating earnings. The major culprit there was continued softness in the sale of titanium dioxide, a whitening agent, of which E I Du Pont De Nemours And Co (NYSE:DD) is the world’s largest producer. As such, it appears that agriculture and chemicals are heading in divergent directions.

Let’s start with agriculture — including bio-engineered seeds and pesticides — and its kindred segments. In addition to ag products, if you add in the results from the industrial bioscience and nutrition and health segments, you’ve accounted for nearly 48.5% of E I Du Pont De Nemours And Co (NYSE:DD)’s total revenues. And, given recent trends, a prediction that the three related operations could account for fully 65% of the company’s total sales within a year may not be a stretch.

That being the case, DuPont’s progress clearly is mimicking that of Monsanto. Indeed, there was a time when the St. Louis-headquartered company also led with its chemicals offerings. But today, through divestitures and other restructurings, virtually all its revenues are derived from agriculturally related products. DuPont already constitutes Monsanto’s chief U.S.-headquartered rival.

A chemicals company no more?

Following Tuesday’s post-earnings call with CEO Ellen Kullman and others on DuPont’s executive team, it’s more-than-slightly apparent that most of the company’s remaining chemicals operations are for sale. There are those who believe that their price tag could hit $11 billion, a haul that would do wonders for both the company’s balance sheet and management’s flexibility in availing itself of new initiatives.

Jettisoning the non-performers

Net debt was actually lowered by $4.2 billion during the second quarter through the application of funds received earlier from the sale of the performance coatings group to Carlyle Group LP (NASDAQ:CG). The private equity firm forked over $4.9 million for the segment, which has subsequently been renamed Axalta Coating Systems.

Think about it. Had performance chemicals been jettisoned prior to the June quarter, by my calculation, the three agriculture and ag-related segments would have constituted, ceteris paribus, nearly 60% of total quarterly corporate revenues. Hence, my prognostication above may be less than gutsy. It’s also noteworthy that that sort of strengthening would be ladled upon a company whose shares have already risen by 25% year to date.

A pair of special strengths

In essence, all this stacks up to constitute a pair of key reasons why I believe that DuPont almost certainly will gain in strength and attractiveness during the remainder of this year and beyond:

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.